CBD Melatonin AKBA Triple Combination for Pancreatic Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pancreatic cancer are inadequate, with pancreatic ductal adenocarcinoma (PDAC) being highly aggressive and incurable, and existing combinations of Cannabidiol (CBD) and Melatonin (MLT) have not been thoroughly tested together with AKBA for their synergistic effects.
Innovation Solution
A multi-component composition of Cannabidiol (CBD), Melatonin (MLT), and AKBA is developed, which is shown to induce cytotoxicity in PDAC cell lines, with combinations of these compounds demonstrating synergistic effects in reducing cell viability and modulating cancer pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for pancreatic cancer are used, then the standard of care is maintained, but the treatments are inadequate and the cancer remains highly aggressive and incurable
Solution Approach 1:
The patent combines three distinct compounds (CBD, MLT, and AKBA) into a single therapeutic regimen to treat pancreatic cancer. This combination approach merges the anti-tumor effects of each individual compound to create a more effective treatment than any single agent alone, directly addressing the inadequacy of current monotherapies.
Solution Approach 2:
The invention uses a composite therapeutic approach by combining compounds with different mechanisms of action (CBD affecting cannabinoid receptors and inflammation, MLT affecting oxidative stress and apoptosis, AKBA affecting NF-κB pathway). This composite strategy creates a multi-faceted attack on the cancer that overcomes the limitations of single-agent therapies.
2Reliability
If combinations of CBD and MLT are used, then some antitumor effect is achieved, but their synergistic effects with AKBA have not been thoroughly tested
Solution Approach 1:
The patent performs preliminary in vitro and in vivo studies to establish the synergistic effects of the CBD-MLT-AKBA combination before clinical application. These preliminary experiments demonstrate enhanced anti-tumor activity compared to individual compounds or pairwise combinations, providing a foundation for further development and reducing the risk of failed clinical trials.
Data Source
AI summary
The present disclosure relates to the use of suitable compounds such as cannabidiol (CBD), melatonin (MLT), acetyl-11-keto-beta-boswellic acid (AKBA), or combinations thereof for treatment of pancreatic cancer and/or similar conditions, diseases or disorders.